Safe Harbor Statement

Size: px
Start display at page:

Download "Safe Harbor Statement"

Transcription

1 Active Biotech AB

2 Safe Harbor Statement Certain statements made during the course of this presentation are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the company, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements. Statements made during the course of this presentation that are forward-looking are based on the company s current beliefs regarding a large number of factors affecting its business. There can be no assurance that (i) the company has correctly measured or identified all of the factors affecting its business or the extent of their likely impact, (ii) the available information with respect to these factors on which the Company s analysis is based is complete or accurate, (iii) the company s analysis is correct or (iv) the Company s strategy, which is based in part on this analysis, will be successful. All forward-looking statements speak only as of the date of this presentation or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by this cautionary statement. The company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this presentation. 2

3 Company overview Swedish Biotechnology Company Core competence in Autoimmune/Inflammatory diseases and Cancer Spin out from Pharmacia 1998 Listed company NASDAQ OMX Nordic: ACTI Share price SEK (5.85 USD), market cap SEK 2.9 B (438 MUSD) as of February 24, 2014 A total of 59 employees 3

4 Active Biotech Pipeline 4

5 MS pathology and disease progression Relapsing-Remitting Secondary Progression Clinical Disability Clinical Threshold Brain Volume Inflammation Axonal Loss Frequent inflammation, demyelination, axonal transection, plasticity, and remyelination Continuing inflammation, persistent demyelination Infrequent inflammation, chronic axonal degeneration, gliosis Ref: Compston A, Coles A. Lancet. 2002;359:

6 Current Multiple Sclerosis Treatment Landscape Drugs on the market and in Phase III development Immunosuppressant Injectable Lemtrada Daclizumab (PIII) Tysabri Oral Gilenya Aubagio (Teriflunomide) Immunomodulator Copaxone Interferons Plegridy (PEG-interferon) Nerventra (laquinimod, PIII) Tecfidera (BG-12) PIII: In Phase III development 6

7 Laquinimod for the treatment of MS Oral, once-daily CNS-active disease-modifying treatment for MS Delaying disability progression (34.2%*), reducing flares (21.4%*) and brain atrophy (30%*) Good safety profile in a large patient population - 7,490 patient years - Some patients exposed for more than seven years A committed and established partner in Teva An ongoing clinical development program EU market application (MAA) for the treatment of RRMS: negative opinion from the CHMP January 2014; re-examination requested * Data from an integrated analysis of two Phase III studies (Allegro and Bravo). 7

8 Laquinimod clinical development Relapsing Remitting Multiple Sclerosis (RRMS) CONCERTO - a third Phase III study ongoing under a SPA - Two doses (0.6mg and 1.2mg) in approx. 1,800 RRMS patients for up to 24 months will be evaluated - Primary endpoint confirmed disability progression as measured by the Expanded Disability Status Scale (EDSS) Other indications Clinical studies in Huntington s disease and Primary Progressive Multiple Sclerosis (PPMS) to be initiated 2014 Further clinical development in Crohn s disease on hold until a clearer clinical strategy has been defined 8

9 Laquinimod Commercial Development and Marketing Agreement Teva Pharmaceutical Industries Teva has global exclusive rights to develop, register, manufacture and commercialize laquinimod since 2004 Teva conducts and funds further clinical development of drug Expected to generate USD 92 million in overall milestones whereof USD 22 million received so far Active Biotech to receive tiered double digit royalties on future sales - 15 year royalty period on country-by-country basis - Higher royalty level in the Nordic/Baltic territory 9

10 Prostate cancer Increasing disease progression 2-4 years Median survival months Diagnosis Surgery/radiation Hormonal treatment (approx. 50% of patients) Wait for progression Pre-chemo Taxotere + Pred. Post-chemo Local PC Metastatic CRPC Targeting AR Injectable Oral Zytiga Xtandi Orteronel (PIII) Over 400,000 new prostate cancer patients diagnosed annually Prostate cancer market 2013E; 7 BUSD 1) Non-AR Prostvac (PIII) Yervoy (PIII) Provenge Custirsen (PIII) Jevtana Xofigo (alpharadin) Tasquinimod (PIII) Cabozantinib (PIII) 1) Credit Suisse Oct

11 Tasquinimod - a new first-in-class oral anti-cancer therapy A unique MoA targeting the tumor s microenvironment, mainly by binding the S100A9 protein Tasquinimod, potentially a new therapeutic option for chemo naïve patients with metastatic CRPC (1) Adapted from Raymond et al, Cancer Chemother Pharmacol, 2013

12 Tasquinimod: Treating castrate resistant prostate cancer (CRPC) Phase II Disease progression: bone scan or CT scan, cancer pain, pathological event 206 asymptomatic metastatic CRPC patients in the US, Canada and Sweden 2:1 randomization 1.0 mg tasquinimod vs placebo Results 69 % of tasquinimod patients vs 34 % of placebo patients had not progressed at 6 months (p<0.0001) 1). Median Progression Free Survival 7.6 vs 3.3 months (p=0.0042) OS data 2) supports that the observed increase in PFS will translate into an increased OS in a trial with sufficient statistical power Placebo switch on tasquinimod 1) Pili et al, JCO Oct 20, 2011: ) Armstrong et al, Clin Cancer Res

13 Ongoing Tasquinimod Phase III Trial Diagnosis Surgery/radiation Hormonal treatment (approx. 50% of patients) Wait for progression Pre-chemo Taxotere + Pred. Post-chemo Local PC Metastatic CRPC Indication: Primary endpoint: Metastatic castrate resistant prostate cancer (mcrpc) pre-chemo Radiographic Progression Free Survival (rpfs) Key secondary endpoint: Overall survival (OS) Study design: Regions: Randomized, double-blind placebo-controlled Global including US/Canada, Europe & China No. of patients: 1,245 Study status: Patient recruitment completed Dec 2012 Estimated filing: 2015 Coordinating investigator: Michael A. Carducci, Johns Hopkins University, Baltimore, US 13

14 Tasquinimod Phase III Analysis plan Primary radiographic progression-free survival (rpfs) analysis at the same time as the first interim overall survival (OS) analysis Time point for the OS interim analysis will be driven by the number of OS events 14

15 Tasquinimod Further Clinical Development Ph III Diagnosis Surgery/radiation Hormonal treatment (approx. 50% of patients) Wait for progression Pre-chemo Taxotere + Pred. Post-chemo Local PC Metastatic CRPC Prostate cancer Ph II Phase II proof of concept clinical study ( Switch maintenance ) of tasquinimod as maintenance therapy in patients with mcrpc who have not progressed after a first line docetaxel based chemotherapy (Ipsen) Phase I investigator sponsored clinical trial, led by Dr. Andrew Armstrong at Duke University Hospital, US ( Tasquinimod and Jevtana) Ph I Other cancers Phase IIa study with tasquinimod in metastatic renal, hepatic, ovarian and gastric cancer (Ipsen) 15

16 Tasquinimod Co-development with Ipsen Partnership announced April 18, 2011 Up to 200 M, including 25 M upfront and 32 M milestones received so far, and additional payments (upon achievement of clinical, regulatory and commercial milestones) Ipsen will pay Active Biotech progressive double-digit royalties on its net sales Active Biotech will be responsible for and finance the ongoing phase III trial Active Biotech granted Ipsen exclusive rights to commercialize tasquinimod worldwide, except for North and South America and Japan where Active Biotech retains all commercial and marketing rights 16

17 Renal Cell Carcinoma (RCC) 180,000 new cases annually 1) RCC market 2011 USD 2.7 billion 2) Approx. 50% cured Diagnosis Surgery Metastases approx. 50% of patients 5-year survival 5-15 % Therapy Disease progression 1) Cowen Therapeutic Categories Outlook March ) EvaluatePharma March

18 ANYARA Therapeutic principle: Selective drug retention in tumor tissue Activation and targeting of effector T cells Direct and indirect tumor cell killing ANYARA Direct killing by CTL SEA/E-120 C H V H 5T4(V14) T lymphocyte ANYARA 5T4 Tumor cell C L V L 5T4(V18) TCR Superantigen Anti-5T4 Fab TNF-α IFN-γ 18

19 ANYARA: Phase II/III trial in RCC Number of patients 513 Randomization Countries Primary endpoint IFNα vs ANYARA+IFNα UK, Ru, Uk, Bu, Ro (50 sites) Overall survival From Phase I to Phase II/III powered for OS analysis in RCC Primary endpoint not reached Subgroup analysis demonstrated proof of concept Doubling of PFS and OS in 25% of patients Good safety profile, in line with previous observations; most common adverse events were grade 1-2 fever, nausea or vomiting 19

20 Phase II/III Subgroup Analysis The 25 % of patients with low/normal levels of the biomarker IL-6 at baseline and expected anti-superantigen antibody levels, showed a statistically significant treatment advantage on both OS and PFS Baseline IL-6 Median IL-6 normal/low Anti-SAg expected Median Baseline Anti-SAg OS for the ANYARA group 63.3 months vs 31.1 months for interferon-α, (p=0.02, HR=0.59) PFS 13.7 vs 5.8 months (p=0.016, HR=0.62) The subgroup accounts for 40-50% of the total number of advanced RCC patients in North America and Western Europe Future development strategies discussed with regulatory authorities Next step a pivotal trial to treat a biomarker-defined group of renal cancer patients in second-line therapy to start only when an out-licensing agreement has been reached with a partner 20

21 Systemic sclerosis (SSc) Orphan indication - 1 to 3 per 10,000 in the US & EU Chronic autoimmune disease of unknown cause Fibrosis and vascular abnormalities affecting the skin, subcutaneous tissue, muscles and internal organs such as gastrointestinal tract, lungs, heart and kidneys Clinically heterogeneous; autoantibody production, fibrosis and vascular damage Current treatment aimed at controlling symptoms and preventing complications Paquinimod (57-57): Oral Treatment of SSc Quinoline molecule previously in clinical development for treatment of SLE Orphan Medicinal Product status for the treatment of SSc granted in the EU Exploratory clinical study in SSc concluded: - 9 patients - safety - evaluate effects on disease related biomarkers Next step a Phase II study in systemic sclerosis - will commence only when an outlicensing agreement has been reached with a partner 21

22 The ISI ( Inhibition of S100 Interactions ) Project Background Quinolines bind S100A9 (PLoS Biology April 2009) S100A9 interacts with the pro-inflammatory RAGE and TLR4 receptors Inhibition of S100A9/TLR4 interactions delays tumor growth (PLoS ONE March 2012) ON OFF = RAGE = TLR4 = S100 The ISI Project First indication oncology Development of NCE s that target S100 protein interactions Patent applications filed First CD selection Q = compound 22

23 Company information

24 Financials January December 2013 MSEK MUSD Jan - Dec Jan - Dec Net sales 116,0 227,9 17,8 35,1 Operating loss -209,0-163,2-32,2-25,1 Loss after tax -212,1-175,0-32,6-26,9 Cash on hand at December 31, 2013: MSEK 376,2 (57,9 MUSD) SEK/USD: 6,50 24

25 Share information Active Biotech market cap (Feb 24, 2014) SEK 2.9 billion USD 438 million Major shareholders (January 31, 2014) Number of shares: 74.9 million MGA Holding % Nordstjernan % Investor % 3rd AP fund % Avanza Pension % EFG Bank % JPM Chase % All other % Total % Number of shareholders whereof 10 largest 60.6% whereof 20 largest 68.0% Ownership categories Swedish owners 83.9% Foreign owners 16.1% 25

26

Active Biotech AB. January, 2014

Active Biotech AB. January, 2014 Active Biotech AB January, 2014 Safe Harbor Statement Certain statements made during the course of this presentation are forward-looking statements. Such forward-looking statements involve known and unknown

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011

More information

Contents. Annual General Meeting. Annual Report 2008

Contents. Annual General Meeting. Annual Report 2008 Annual Report 2008 Contents Active Biotech in brief 3 Comments from the CEO 4 Directors report 6 THE GROUP Income Statement 13 Cash-flow statement 13 Balance Sheet 13 Changes in shareholders equity 14

More information

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September

More information

Personalised Medicine in MS

Personalised Medicine in MS Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective

More information

Growth in revenue from MS drugs has been driven largely by price increases over the last several years.

Growth in revenue from MS drugs has been driven largely by price increases over the last several years. March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January

More information

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents

More information

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

More information

A neurologist would assess your eligibility and suitability for the DMTs.

A neurologist would assess your eligibility and suitability for the DMTs. Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.

More information

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective

More information

Multiple Sclerosis Drug Discoveries - What the Future Holds

Multiple Sclerosis Drug Discoveries - What the Future Holds Brochure More information from http://www.researchandmarkets.com/reports/1408035/ Multiple Sclerosis Drug Discoveries - What the Future Holds Description: The recent approval in the US of Novartis' orally

More information

Progress in MS: Current and Emerging Therapies

Progress in MS: Current and Emerging Therapies Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

Kanıt: Klinik çalışmalarda ZYTIGA

Kanıt: Klinik çalışmalarda ZYTIGA mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen

More information

J.P. Morgan Cazenove Therapeutic Seminar

J.P. Morgan Cazenove Therapeutic Seminar Jannan, MS J.P. Morgan Cazenove Therapeutic Seminar David Meeker - CEO, Genzyme June 25, 2012 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private

More information

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

Which injectable medication should I take for relapsing-remitting multiple sclerosis? Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have

More information

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif - PRESS RELEASE Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM* (Alemtuzumab) Compared With Rebif in Phase lll Trial - Patients treated with

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine

More information

REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Prostate Cancer: Key Metrics in the 9MM, 2013 2023 2013 Epidemiology

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

News on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS

News on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS News on modifying diseases therapies Michel CLANET CHU Toulouse France ECTRIMS Current treatment strategies Future oral treatments Future non oral treatments Drug safety and risks CIS at risk of MS Active

More information

Prostate Cancer Studies

Prostate Cancer Studies Prostate Cancer Studies STUDIES CURRENTLY RECRUITING MDV3100-14 A multinational, Phase 3, Randomized, Double- Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastic

More information

CAN-FITE BIOPHARMA LTD.

CAN-FITE BIOPHARMA LTD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month

More information

Genzyme s Multiple Sclerosis Franchise Featured at AAN

Genzyme s Multiple Sclerosis Franchise Featured at AAN PRESS RELEASE Genzyme s Multiple Sclerosis Franchise Featured at AAN - Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs - Paris, France March 13, 2013 Sanofi (EURONEXT:

More information

PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022. Multiple

PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022. Multiple Brochure More information from http://www.researchandmarkets.com/reports/2541548/ PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022 Description: PharmaPoint: Multiple

More information

BNC105 PHASE II RENAL CANCER TRIAL RESULTS

BNC105 PHASE II RENAL CANCER TRIAL RESULTS ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient

More information

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011 Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare

More information

Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis

Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness

More information

Integrating New Treatments: A Case Based Approach

Integrating New Treatments: A Case Based Approach Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide

More information

The submission positioned dimethyl fumarate as a first-line treatment option.

The submission positioned dimethyl fumarate as a first-line treatment option. Product: Dimethyl Fumarate, capsules, 120 mg and 240 mg, Tecfidera Sponsor: Biogen Idec Australia Pty Ltd Date of PBAC Consideration: July 2013 1. Purpose of Application The major submission sought an

More information

Before, Frank's immune cells could

Before, Frank's immune cells could Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years

More information

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013 Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012

More information

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January

More information

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

UPDATED INVESTOR PRESENTATION June 2015

UPDATED INVESTOR PRESENTATION June 2015 UPDATED INVESTOR PRESENTATION June 2015 Forward-looking Statements All statements in this presentation other than those of historical fact, including statements regarding our clinical development plans

More information

Understanding How Existing and Emerging MS Therapies Work

Understanding How Existing and Emerging MS Therapies Work Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of

More information

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center Multiple Sclerosis Update Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center None Disclosures First of All. Why is my talk in the Neurodegenerative hour? I respectfully object! Case

More information

News Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma

News Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Markus Talanow +49 6151 72 7144 Investor Relations +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor

More information

Treatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone )

Treatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone ) Treatments for MS: Immunotherapy There are currently several disease-modifying therapies approved for people with MS in Australia. These therapies, called immunotherapies, work to reduce disease activity

More information

Affitech A/S reports financial result for the first six months of 2012

Affitech A/S reports financial result for the first six months of 2012 Release no. 23/2012 Affitech A/S reports financial result for the first six months of 2012 Clinical trials sites initiated in Russia in late June 2012 by Affitech s collaboration partner IBC Generium for

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous

More information

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required

More information

New Advances in Cancer Treatments. March 2015

New Advances in Cancer Treatments. March 2015 New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within

More information

MOLOGEN AG. Dr. Matthias Schroff Chief Executive Officer Dr. Alfredo Zurlo Chief Medical Officer. Roadshow Abu Dhabi, Dubai April 2015

MOLOGEN AG. Dr. Matthias Schroff Chief Executive Officer Dr. Alfredo Zurlo Chief Medical Officer. Roadshow Abu Dhabi, Dubai April 2015 Dr. Matthias Schroff Chief Executive Officer Dr. Alfredo Zurlo Chief Medical Officer Roadshow Abu Dhabi, Dubai April 2015 Disclaimer Certain statements in this presentation contain formulations or terms

More information

Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis

Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness of teriflunomide

More information

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

More information

Disease Modifying Therapies (DMTs) in Multiple Sclerosis

Disease Modifying Therapies (DMTs) in Multiple Sclerosis Disease Modifying Therapies (DMTs) in Multiple Sclerosis Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology Conflict of Interest Dr. Stobbe has no conflicts of

More information

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Laquinimod Polman, C. et al. Neurology 2005;64:987-991

Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Multicenter, double-blind, randomized trial, patients with RR MS received 0.1 mg or 0.3 mg laquinimod or placebo as three daily tablets for 24 weeks

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine

More information

New treatments in MS What s here and what s nearly here

New treatments in MS What s here and what s nearly here 5 th MS Research Day, June 14 th 2014 New treatments in MS What s here and what s nearly here David Miller Queen Square MS Centre at UCL and UCLH Course of MS and its treatment Relapsing remitting Disability

More information

Lemtrada (alemtuzumab)

Lemtrada (alemtuzumab) Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 08/2015 Origination: 08/2015 Next Review: 08/2016 Policy BCBSKC will provide coverage for Lemtrada (alemtuzumab) when it is determined to be

More information

Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004

Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Medication Policy Manual Policy No: dru108 Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW EFFICACY IN PEOPLE WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN LARGE PHASE III STUDY

GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW EFFICACY IN PEOPLE WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN LARGE PHASE III STUDY NEWS RELEASE Media Contact: Tara Iannuccillo (650) 467-6800 Investor Contacts: Stefan Foser Karl Mahler (650) 467-2016 011 41 61 687 8503 GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW

More information

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields

More information

STRATEGY PROGRAM NEXT LEVEL BERLIN, 9 JUNE 2016

STRATEGY PROGRAM NEXT LEVEL BERLIN, 9 JUNE 2016 STRATEGY PROGRAM NEXT LEVEL BERLIN, 9 JUNE 2016 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments, as well as negations of

More information

Aeterna Zentaris. 11 th Annual Needham Healthcare Conference April 3, 2012. Committed to cure

Aeterna Zentaris. 11 th Annual Needham Healthcare Conference April 3, 2012. Committed to cure 11 th Annual Needham Healthcare Conference April 3, 2012 Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities

More information

Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011

Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011 Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,

More information

MEDIVATION, INC. FORM 8-K. (Current report filing) Filed 01/31/14 for the Period Ending 01/28/14

MEDIVATION, INC. FORM 8-K. (Current report filing) Filed 01/31/14 for the Period Ending 01/28/14 MEDIVATION, INC. FORM 8-K (Current report filing) Filed 1/31/14 for the Period Ending 1/28/14 Address 525 MARKET STREET 36TH FLOOR SAN FRANCISCO, CA 9415 Telephone 415-543-347 CIK 111835 Symbol MDVN SIC

More information

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination

More information

Incorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice

Incorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice Incorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice Please see Important Safety Information throughout this presentation and full Prescribing Information available at this 2014 Bayer

More information

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine

More information

Multiple Sclerosis. Global Drug Forecast and Market Analysis to 2022 Event-Driven Update. GDHC34PIDR / Published April 2013

Multiple Sclerosis. Global Drug Forecast and Market Analysis to 2022 Event-Driven Update. GDHC34PIDR / Published April 2013 Multiple Sclerosis Global Drug Forecast and Market Analysis to 2022 Event-Driven Update GDHC34PIDR / Published April 2013 Executive Summary The table below presents the key metrics for multiple sclerosis

More information

Corporate Presentation June 2, 2015

Corporate Presentation June 2, 2015 Corporate Presentation June 2, 2015 SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these

More information

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The

More information

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd.

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Oncology Strategy and Acquisition Significance 1 Commitment to Oncology Entering the Oncology Area Globally External

More information

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and

More information

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON First-line DMTs Reduce Relapse Frequency by ~30% vs. Placebo Frequency of relapse with various DMTs, based

More information

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,

More information

New Treatment Options for MS Patients: Understanding risks versus benefits

New Treatment Options for MS Patients: Understanding risks versus benefits New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS

More information

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health

More information

Original Policy Date

Original Policy Date MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer

More information

1. Comparative effectiveness of alemtuzumab

1. Comparative effectiveness of alemtuzumab Cost-effectiveness of alemtuzumab (Lemtrada ) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features The NCPE has issued

More information

Biotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015

Biotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015 Biotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015 1 Timo Veromaa President & CEO 2 Company Highlights 2014 through Q1 2015 Continued advances

More information

Company Presentation June 2011 Biotest AG 0

Company Presentation June 2011 Biotest AG 0 Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and

More information

Chapter 10. Summary & Future perspectives

Chapter 10. Summary & Future perspectives Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral

More information

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

The Ultimate Healthcare & Biotechnology Event in 2010. Deborah Rathjen CEO & Managing Director 24 March 2010

The Ultimate Healthcare & Biotechnology Event in 2010. Deborah Rathjen CEO & Managing Director 24 March 2010 The Ultimate Healthcare & Biotechnology Event in 2010 Deborah Rathjen CEO & Managing Director 24 March 2010 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking"

More information

Il carcinoma prostatico metastatico: Quale prima linea? Quale terapia nelle linee successive? Claudia Caserta S.C. di Oncologia Terni

Il carcinoma prostatico metastatico: Quale prima linea? Quale terapia nelle linee successive? Claudia Caserta S.C. di Oncologia Terni Il carcinoma prostatico metastatico: Quale prima linea? Quale terapia nelle linee successive? Claudia Caserta S.C. di Oncologia Terni METASTATIC PROSTATE CANCER DIFFERENT THERAPEUTIC APPROACHES Metastatic

More information

Updates in Prostate Cancer Therapy Sequencing Strategies. Debates and Didactics in Hematology and Oncology. July 26, 2015.

Updates in Prostate Cancer Therapy Sequencing Strategies. Debates and Didactics in Hematology and Oncology. July 26, 2015. Updates in Prostate Cancer Therapy Sequencing Strategies Debates and Didactics in Hematology and Oncology July 26, 2015. Sea Island, GA Bradley C. Carthon, MD. Ph.D. Assistant Professor, Winship Cancer

More information

Recruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed

Recruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has

More information

ORAL MEDICATIONS FOR MS! Gilenya and Aubagio

ORAL MEDICATIONS FOR MS! Gilenya and Aubagio ORAL MEDICATIONS FOR MS! Gilenya and Aubagio Champions against MS 4/20/13 Alexandra Goodyear, MD Stanford University Oral Medications Since 2010, 3 new oral medications for MS: Gilenya 2010 Aubagio 2012

More information

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for

More information

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of

More information

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

More information